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BSTRACT
 
Background
 
The sialic acid analogue zanamivir
(GG167) is a selective inhibitor of influenza A and B
virus neuraminidases. These viral enzymes are es-
sential for the release of virus from infected cells, and
they may also reduce the inactivation of virus by res-
piratory secretions. When administered experimen-
tally directly to the respiratory tract, zanamivir has
potent antiviral effects. We assessed the therapeutic
activity of zanamivir in adults with acute influenza.
 
Methods
 
We conducted separate randomized, dou-
ble-blind studies in 38 centers in North America and
32 centers in Europe during the influenza season of
1994–1995. A total of 417 adults with influenza-like
illness of 
 

 
48 hours’ duration were randomly as-
signed to one of three treatments: 6.4 mg of zana-
mivir by intranasal spray plus 10 mg by inhalation,
10 mg of zanamivir by inhalation plus placebo spray,
or placebo by both routes. Treatments were self-
administered twice daily for five days.
 
Results
 
Of 262 patients with confirmed influenza-
virus infection (63 percent of all patients), the medi-
an length of time to the alleviation of all major symp-
toms was one day shorter (four days vs. five days) in
the 88 patients given inhaled and intranasal zana-
mivir (P
 

 
0.02) and the 85 patients given inhaled
zanamivir alone (P
 

 
0.05) than in the 89 patients giv-
en placebo. Among the infected patients who were
febrile at enrollment and among those who began
treatment within 30 hours after the onset of symp-
toms, the median time to the alleviation of major
symptoms was four days in both zanamivir groups
and seven days in the placebo group (P
 

 
0.01). Viral
titers of nasal washings in the group given inhaled
and intranasal zanamivir were significantly lower
than those in the placebo group. The topically ad-
ministered zanamivir was well tolerated.
 
Conclusions
 
In adults with influenza A or B virus
infections, direct administration of a selective neura-
minidase inhibitor, zanamivir, to the respiratory tract
is safe and reduces symptoms if begun early. (N Engl
J Med 1997;337:874-80.)
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WO general measures are available to re-
duce the impact of influenza: immuniza-
tion with inactivated vaccines and antiviral
prophylaxis and therapy with amantadine
and rimantadine.
 
1
 
 The usefulness of amantadine and
rimantadine is limited by an antiviral spectrum re-
stricted to influenza A viruses, their uncertain effec-
T
 
tiveness in severe influenza or in preventing complica-
tions, side effects, and the emergence of drug-resistant
variants.
 
2
 
 Consequently, there is a continuing need
for more effective antiviral agents to manage influenza
infections.
The sialic acid analogue zanamivir (GG167) is a
potent, specific inhibitor of influenzavirus neuramin-
idase.
 
3,4
 
 This enzyme, essential for replication in vi-
tro,
 
5
 
 cleaves terminal sialic acid residues from glyco-
conjugates to allow the release of virus from infected
cells, prevent the aggregation of virus, and possibly
reduce viral inactivation by respiratory mucus.
 
6,7
 
 Zana-
mivir inhibits a range of influenza A and B viruses in
vitro.
 
8,9
 
 Topically applied zanamivir is active in animal
models of influenza,
 
3,8,10
 
 although systemically ad-
ministered drug has little antiviral activity. In adults
experimentally inoculated with influenza A virus,
prophylactic intranasal zanamivir was highly protec-
tive against infection and febrile illness.
 
11
 
 Treatment
beginning one day after viral challenge also reduced
peak viral titers by a factor of approximately 100 and
reduced the frequency of febrile illness by 85 per-
cent. We undertook studies to determine whether
topical application of zanamivir would prove effective
in the treatment of naturally occurring acute influen-
za. Because influenza commonly involves the lower
respiratory tract,
 
12
 
 both intranasal and inhaled forms
of the drug were tested.
 
METHODS
 
Two parallel multicenter trials were conducted in North Amer-
ica (38 centers) and Europe (32 centers) during the 1994–1995
influenza season. Both were randomized, double-blind, and pla-
cebo-controlled in design and tested the same regimen of drug
treatment.
 
Patients
 
Previously healthy persons who were at least 18 years old (at
least 13 years in North America) with an acute influenza-like ill-
ness of 
 

 
48 hours’ duration during documented influenzavirus
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circulation in the community were enrolled. Illness was defined
as the presence of fever and at least two other symptoms (head-
ache, myalgia, cough, and sore throat). Suspected bacterial infec-
tion or recent use of antimicrobial drugs, immunization with
influenza vaccine for the current season, pregnancy or breast-
feeding, concurrent use of intranasal or inhaled medications, and
underlying conditions for which influenza immunization is cur-
rently recommended were reasons for exclusion. Women of child-
bearing potential were enrolled if they were using an acceptable
means of contraception and had a negative urine pregnancy test.
Subjects provided written informed consent using a form ap-
proved by an appropriate institutional review or ethics committee.
 
Study Procedures
 
At enrollment, a medical history was obtained, a physical ex-
amination was conducted, and a complete blood count, blood
chemical analyses, and urinalysis were performed. Serum for he-
magglutination-inhibition tests (performed at the University of
Rochester, N.Y., or the National Institute for Biological Standards
and Control, United Kingdom) and nose and throat swabs or na-
sal washings for viral culture were also collected.
Patients were randomly assigned to receive one of three treat-
ments: 10 mg of zanamivir by inhalation by mouth plus 6.4 mg
by intranasal spray, 10 mg of zanamivir by inhalation plus placebo
nasal sprays, or placebo by both routes. Treatments were self-
administered twice daily for five days. A Diskhaler device (Glaxo
Wellcome, Ware, United Kingdom) was used to administer two
inhalations of a dry powder containing 20 mg of lactose and 5 mg
of zanamivir by mouth. The aerodynamic mass median diameter
of the micronized powder was estimated to be approximately 3.0
 
m
 
M. Lactose alone served as the vehicle control. The nasal aque-
ous spray was administered as two 0.1-ml sprays per nostril. Com-
pliance with the study medications was determined by having the
patients keep daily diaries chronicling treatment. Each patient was
given a package of relief medications, which included acetamino-
phen, dextromethorphan hydrobromide, and pseudoephedrine.
The patients recorded their symptoms (nasal stuffiness or runny
nose, sore throat, cough, muscle aches, tiredness or fatigue, head-
ache, loss of appetite, and feverishness) on a diary card each morn-
ing and evening. Severity was rated on a four-point scale in which
a score of 0 indicated no symptoms, a score of 1 mild symptoms,
a score of 2 moderate symptoms, and a score of 3 severe symp-
toms. Patients also recorded their oral temperatures twice daily
and their ability to engage fully in usual daily activities. They re-
turned one to three days after treatment for a follow-up examina-
tion, to provide laboratory samples, and to report any adverse ex-
periences. They also returned during convalescence on days 21 to
28 for hemagglutination-inhibition antibody testing.
At three centers (Rochester, N.Y.; Charlottesville, Va.; and Win-
nipeg, Manitoba), nasal washings were collected on days 2, 4,
6, and 8 for titration of virus. Samples were frozen, and any
that were initially culture-positive were cultured again in Madin–
Darby canine-kidney cells to determine the median tissue-culture
infective dose of virus (log
 
10
 
 TCID
 
50
 
) per milliliter of sample.
 
Statistical Analysis
 
The primary clinical end point was the length of time to the
alleviation of all major symptoms of influenza, as defined by the
absence of feverishness and the presence of no other major symp-
toms (headache, myalgia, cough, and sore throat), or only mild
ones, for at least 24 hours. For the analysis of this end point, the
patients were grouped into 10 categories, from day 1 to day 10
or later, according to the day on which their symptoms resolved.
Patients who withdrew with no evidence of alleviation of symp-
toms were included in the “day 10 or later” category.
 
13
 
 Patients
with influenzavirus infection, defined by the recovery of virus, a
fourfold or greater rise in serum antibody titers on hemaggluti-
nation-inhibition testing, or both, were considered able to be
evaluated in the efficacy analysis. All patients who received the
study drug were assessed for adverse events.
The statistical-analysis strategy involved the combined use of
nonparametric and model-based methods.
 
14
 
 Pairwise comparisons
of intranasal and inhaled zanamivir with placebo and of inhaled
zanamivir with placebo were performed with an extended Man-
tel–Haenszel test, with integer scores stratified according to the
protocol.
 
15
 
 Estimates and confidence intervals for treatment ef-
fects were based on analysis of variance after allowance for effects
due to the study protocol and treatment. The two tests were
viewed as belonging to a hierarchy; no adjustments for multiple
comparisons were made.
Prognostic factors identified as potentially influencing the effi-
cacy of treatment included the study site (North America vs. Eu-
rope), the type of influenzavirus, the duration of symptoms be-
fore entry into the study, and the presence of fever at entry (oral
temperature, 
 

 
37.8°C). Tests of the interaction of each of these
covariates with treatment were performed with analysis of vari-
ance. Where statistically significant interactions were observed,
further subgroup analyses were performed.
Secondary end points included the lengths of time to the re-
sumption of normal activities, to the alleviation of individual
symptoms, to the loss of fever, and to the loss of detectable virus.
The viral shedding area under the curve (AUC) was also deter-
mined.
 
11
 
 The secondary end points were analyzed in the same
manner as the primary end point, except for the viral shedding
AUC, which was analyzed with analysis of covariance to allow for
effects due to base line (day 1 value) and treatment. All analyses
were performed with SAS systems and procedures.
 
Sample Size
 
The calculation of sample size was based on the assumption
that major symptoms would be alleviated by the sixth study day
in approximately 50 percent of influenzavirus-infected placebo re-
cipients. A clinically relevant difference was defined as an increase
in this fraction to 75 percent or greater. A sample of 195 infected
patients (65 per group) is required for a two-tailed test of these
proportions at the 5 percent level of significance and 80 percent
power.
 
16
 
 On the basis of an influenza-infection rate of approxi-
mately 70 percent, each study was designed to recruit 273 pa-
tients. However, neither individually reached its enrollment goal
(111 infected patients in North America and 151 in Europe). Be-
fore the results were unblinded, we decided to perform a com-
bined analysis of the two studies. The resolution of illness and ef-
fects of drug administration were similar in the two trials.
 
RESULTS
 
Patients
 
A total of 220 patients with suspected influenza
were randomly assigned to a treatment group in
North American centers and 197 in European cen-
ters (Table 1). Overall, 63 percent had laboratory
confirmation of influenzavirus infection. The fre-
quency of confirmed infection was higher in Euro-
pean centers (77 percent) than in North American
ones (50 percent), in part because of the greater use
of rapid antigen screening. Of the 262 influenza-
positive illnesses, 56 percent were due to influenza
A virus and 44 percent to influenza B virus. The pre-
dominant strains in North America were H3N2 sub-
types, whereas influenza B infections predominated
in Europe (Table 1). Most infected patients were
culture-positive at entry; the duration of illness be-
fore enrollment averaged 31 hours in the three treat-
ment groups. Other demographic characteristics of
enrolled patients and their severity of illness were
generally similar (Table 1), although an excess of
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smokers was present in the group assigned to intra-
nasal and inhaled zanamivir.
One patient randomly assigned to the placebo
group failed to take the study drug. Eight other pa-
tients in the placebo group withdrew, as did 10 as-
signed to inhaled zanamivir and 10 assigned to in-
haled and intranasal zanamivir. The most common
reason for withdrawal was failure to return for the
scheduled study visits.
The use of relief medications was common. The
cumulative frequency of the use of acetaminophen
(76 percent in the placebo group, 76 percent in the
group given inhaled zanamivir, and 74 percent in
the group given intranasal and inhaled zanamivir),
cough medications (64 percent, 54 percent, and 52
percent, respectively), and decongestants (48 per-
cent, 57 percent, and 40 percent) did not differ sig-
nificantly during the treatment period.
 
Clinical Efficacy
 
For the 262 patients with confirmed influenza, the
median time to the alleviation of major symptoms
was five days in the placebo groups in both trials.
This time was one day shorter in the groups assigned
to inhaled zanamivir (P
 

 
0.05) and intranasal and in-
haled zanamivir (P
 

 
0.02). By the third study day the
proportion of patients whose illness was alleviated
was higher in the zanamivir groups than in the pla-
cebo group, and this difference was maintained after
the cessation of treatment (Fig. 1). No obvious dif-
ferences were noted between the zanamivir groups.
Analysis of the intention-to-treat population re-
vealed findings similar to those for the infected pop-
ulation, although the size of the treatment effects
was smaller (Table 2). No evidence of benefit was
observed in uninfected patients (data not shown).
Further modeling analyses indicated that zanamivir
was more effective in patients treated early, within
30 hours after the onset of symptoms (P
 

 
0.02 for
the interaction with treatment), and in patients who
were febrile at entry (P
 

 
0.05 for the interaction
with treatment). There was no evidence of a differ-
ence in the treatment effect between type A and
type B influenzavirus infections or between study lo-
cations (North America vs. Europe). Placebo recip-
ients with documented fever on enrollment had
more prolonged illness, and the median time to the
alleviation of symptoms in this subgroup was two
days longer than for the placebo-treated patients as
a whole (Table 2). Among febrile patients who re-
ceived zanamivir, symptoms were alleviated a median
of three days sooner than in the placebo group
(P
 

 
0.01 for the comparison of placebo with inhaled
zanamivir; P
 

 
0.001 for the comparison of placebo
with intranasal and inhaled zanamivir). In addition,
the febrile zanamivir recipients resumed their nor-
mal activities a median of one day sooner than the
febrile placebo recipients (Table 3). Those without
fever on enrollment had no significant benefit of
treatment (Table 2).
Among patients who were treated earlier in the
course of illness (
 

 
30 hours after the onset of symp-
toms), who represented half of the enrolled influen-
za-infected population, the administration of zana-
 
*Plus–minus values are means 
 

 
SD.
†The presence of infection was defined on the basis of isolation of virus, an increase in antibody titer of fourfold or more on hemagglutination-inhibition
testing, or both.
‡The hemagglutination-inhibition test was used to measure antibodies in serum samples.
§The score is expressed as a percentage of the maximal possible score of 24.
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PLACEBO
 
(
 
N
 

 
40)
 
INHALED
ZANAMIVIR
 
(
 
N
 

 
37)
 
INHALED
 
 
 
AND
INTRANASAL
ZANAMIVIR
 
(
 
N
 

 
34)
 
PLACEBO
 
(
 
N
 

 
49)
 
INHALED
ZANAMIVIR
 
(
 
N
 

 
48)
 
INHALED
 
 
 
AND
INTRANASAL
ZANAMIVIR
 
(
 
N
 

 
54)
 
PLACEBO
 
(
 
N
 

 
89)
 
INHALED
ZANAMIVIR
 
(
 
N
 

 
85)
 
INHALED
 
 
 
AND
INTRANASAL
ZANAMIVIR
 
(
 
N
 

 
88)
Type of infection — no. (%)†
Influenza A
Influenza B
31 (78)
9 (22)
24 (65)
13 (35)
27 (79)
7 (21)
22 (45)
27 (55)
20 (42)
28 (58)
23 (43)
31 (57)
53 (60)
36 (40)
44 (52)
41 (48)
50 (57)
38 (43)
Culture positive — no. (%) 34 (85) 30 (81) 31 (91) 48 (98) 45 (94) 49 (91) 82 (92) 75 (88) 80 (91)
 

 
Fourfold increase in antibody titer
— no. (%)‡
17 (42) 21 (57) 15 (44) 30 (61) 33 (69) 34 (63) 47 (53) 54 (64) 49 (56)
Male sex — no. (%) 22 (55) 24 (65) 22 (65) 26 (53) 26 (54) 28 (52) 48 (54) 50 (59) 50 (57)
Age — yr 31
 

 
14 29
 

 
12 30
 

 
13 35
 

 
11 32
 

 
10 34
 

 
11 33
 

 
12 31
 

 
11 32
 

 
12
Smoker — no. (%) 9 (22) 9 (24) 9 (26) 7 (14) 7 (15) 16 (30) 16 (18) 16 (19) 25 (28)
Duration of symptoms before study 
entry — hr
3013 2912 2911 3012 3312 3312 3012 3112 3112
Symptom score at enrollment — % of 
maximal score§
6116 6016 6016 5819 5718 6018 5917 5817 6017
Temperature, 37.8°C — no. (%) 28 (70) 23 (62) 19 (56) 26 (53) 23 (48) 32 (59) 54 (61) 46 (54) 51 (58)
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mivir was associated with a shorter — by three days
— median time to the alleviation of symptoms than
in the placebo group (P0.001 for the comparison
of placebo with inhaled zanamivir; P0.001 for the
comparison of placebo with intranasal and inhaled
zanamivir). The cumulative fraction whose symp-
toms were alleviated increased steadily, so that ap-
proximately 90 percent had no symptoms or only
mild ones through day 9 (Fig. 2). In comparison,
symptoms were alleviated more slowly in the placebo
recipients, and nearly 30 percent had not reached
this end point by day 10. The patients who were
treated earlier with zanamivir resumed their normal
activities a median of one to two days before the re-
spective placebo group (Table 3). In contrast, those
treated more than 30 hours after the onset of symp-
toms had no significant reductions in these measures
(Tables 2 and 3).
Cough was the most persistent individual symp-
tom, lasting a median of four days among placebo
recipients and three days among zanamivir recipi-
ents. Recipients of intranasal zanamivir tended to
have shorter periods of nasal congestion (median,
two days) than the other groups (three days). The
Figure 1. Alleviation of Symptoms in Patients Infected with In-
fluenza A or B Virus Who Were Treated with Inhaled Zanamivir,
Intranasal and Inhaled Zanamivir, or Placebo. 
Alleviation of illness was defined as the absence of feverish-
ness and the presence of no symptoms of headache, muscle
aches, sore throat, and cough, or only mild ones, for at least
24 hours. As the P values indicate, the two zanamivir groups
differed significantly from the placebo group but not from each
other.
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*Alleviation of illness was defined as the absence of feverishness and the presence of no symptoms of headache, muscle aches, sore throat, and cough, or
only mild ones, for at least 24 hours.
†P values were derived from the extended Mantel–Haenszel test. CI denotes confidence interval.
TABLE 2. TIMES TO THE ALLEVIATION OF MAJOR SYMPTOMS OF INFLUENZA.*
VARIABLE PLACEBO INHALED ZANAMIVIR
INHALED AND INTRANASAL 
ZANAMIVIR
COMPARISON OF 
INHALED ZANAMIVIR
AND PLACEBO†
COMPARISON OF 
INHALED AND INTRANASAL 
ZANAMIVIR AND 
PLACEBO†
MEDIAN
MEAN
SD
NO. OF 
SUBJECTS MEDIAN
MEAN
SD
NO. OF 
SUBJECTS MEDIAN
MEAN
SD
NO. OF 
SUBJECTS
DIFFERENCE
(95% CI)
P
VALUE
DIFFERENCE
(95% CI)
P
VALUE
day day day
All subjects (inten-
tion-to-treat 
analysis)
5 6.02.9 144 5 5.32.6 132 4 5.52.8 141 0.7
(1.4 to 0)
0.04 0.6 
(1.2 to 0.1)
0.09
Confirmed influenza 
infection
5 6.32.9 89 4 5.42.7 85 4 5.32.8 88 0.8
(1.7 to 0)
0.05 1.0
(1.8 to 0.1)
0.02
Fever at enrollment 
(temperature, 
37.8°C)
7 6.82.8 54 4 5.32.6 46 4 5.12.5 51 1.4 
(2.5 to 0.4)
0.01 1.8
(2.8 to 0.8)
0.001
No fever at enroll-
ment
4 5.53.0 35 4 5.52.9 39 4 5.73.0 37 0.1 
(1.3 to 1.4)
0.93 0.2 
(1.2 to 1.6)
0.73
Initiation of treat-
ment
30 hr after on-
set of symp-
toms
30 hr after on-
set of symp-
toms
7
4
7.02.7
5.53.0
45
44
4
5
5.12.2
5.83.1
43
42
4
5
4.82.6
5.82.8
42
46
1.9
(2.9 to 0.8)
0.3
(1.0 to 1.5)
0.001
0.68
2.2 
(3.2 to 1.1)
0.3 
(1.0 to 1.5)
0.001
0.70
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duration of fever was relatively brief in all groups
(median, two days), but this analysis was confound-
ed by frequent use of antipyretic drugs.
The incidence of complications of influenza for
which antibiotics were prescribed was 12 percent in
the placebo group, 8 percent in the group given in-
haled zanamivir, and 8 percent in the group given
intranasal and inhaled zanamivir. Otitis media was
diagnosed in 2 percent of influenza-infected pa-
tients, sinusitis in 3 percent, bronchitis in 2 percent,
and pharyngitis and tonsillitis in 2 percent.
Virologic Measures
Among infected patients, the median duration of
viral shedding tended to be shorter among those
given inhaled zanamivir (four days) or intranasal and
inhaled zanamivir (four days) than in those given
placebo (six days). In the group given inhaled and
intranasal zanamivir, the titers of virus recovered in
nasal washings were lower by a mean of 2.1 log10
TCID50 per milliliter on the second treatment day
and by 1.5 log10 TCID50 per milliliter on the fourth
day as compared with placebo (P0.05 for the com-
parison with placebo by analysis of the AUC). As ex-
pected, no reductions in nasal viral titers were noted
in the group given inhaled zanamivir. None of the
groups had increases in viral titers after the cessation
of therapy.
Among the infected patients, the frequencies of
increases in antibody titers of fourfold or greater on
hemagglutination-inhibition testing did not differ
among the placebo group (53 percent of patients),
the group given inhaled zanamivir (64 percent), and
*P values were derived from the extended Mantel–Haenszel test. CI denotes confidence interval.
TABLE 3. TIMES TO THE RESUMPTION OF USUAL ACTIVITIES.
VARIABLE PLACEBO INHALED ZANAMIVIR
INHALED AND INTRANASAL 
ZANAMIVIR
COMPARISON OF 
INHALED ZANAMIVIR
AND PLACEBO*
COMPARISON OF 
INHALED AND INTRANASAL 
ZANAMIVIR AND 
PLACEBO*
MEDIAN
MEAN
SD
NO. OF 
SUBJECTS MEDIAN
MEAN
SD
NO. OF 
SUBJECTS MEDIAN
MEAN
SD
NO. OF 
SUBJECTS
DIFFERENCE
(95% CI)
P
VALUE
DIFFERENCE
(95% CI)
P
VALUE
day day day
Confirmed influenza 
infection
4 4.92.7 89 4 4.62.8 85 4 4.22.5 88 0.3
(1.1 to 0.4)
0.41 0.8
(1.5 to 0)
0.05
Fever at enrollment 
(temperature, 
37.8°C)
5 5.12.6 54 4 4.52.8 46 4 4.42.4 51 0.6
(1.6 to 0.4)
0.23 0.9
(1.9 to 0.1)
0.06
No fever at enroll-
ment
3 4.52.8 35 4 4.72.9 39 3 3.92.8 37 0.1
(1.1 to 1.4)
0.81 0.5
(1.8 to 0.8)
0.44
Initiation of 
treatment 
30 hr after 
onset of 
symptoms
5 5.42.8 45 4 4.12.6 43 3 3.82.4 42 1.3
(2.3 to 0.2)
0.02 1.7 
(2.7 to 0.6)
0.01
30 hr after
onset of 
symptoms
4 4.42.5 44 5 5.12.9 42 4 4.62.7 46 0.7
(0.5 to 1.8)
0.26 0.2
(1.0 to 1.3)
0.80
Figure 2. Alleviation of Symptoms in Patients Infected with In-
fluenza A or B Virus Who Were Treated within 30 Hours after
the Onset of Symptoms with Inhaled Zanamivir, Inhaled and
Intranasal Zanamivir, or Placebo. 
Alleviation of illness was defined as the absence of feverish-
ness and the presence of no symptoms of headache, muscle
aches, sore throat, and cough, or only mild ones, for at least
24 hours. As the P values indicate, the two zanamivir groups
differed significantly from the placebo group but not from each
other.
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the group given intranasal and inhaled zanamivir (56
percent). Similarly, the mean (SD log2) increase
in titers in paired samples on hemagglutination-inhi-
bition testing did not differ among the groups
(2.21.6, 2.41.4, and 2.11.8, respectively).
Tolerance
Six patients in each group withdrew during treat-
ment. The numbers of patients who missed four or
more doses because of noncompliance or withdrawal
were also similar in the three groups (13 patients in
the placebo group and 8 each in the group given in-
haled zanamivir and intranasal and inhaled zana-
mivir).
Possible drug-related adverse events were reported
by 18 percent of 144 patients assigned to placebo,
23 percent of 132 patients assigned to inhaled zana-
mivir, and 25 percent of 141 patients assigned to
intranasal and inhaled zanamivir. During drug ad-
ministration, adverse events related to the upper res-
piratory tract (9 percent of patients given placebo,
7 percent of those given inhaled zanamivir, and 11
percent of those given intranasal and inhaled zana-
mivir) or gastrointestinal tract (5 percent, 7 percent,
and 9 percent, respectively) were the most common,
but these reactions were difficult to distinguish from
symptoms due to the underlying illness. The fre-
quencies of local irritation of the nose (5 to 6 per-
cent) or eyes (1 percent) were similar in the three
groups. No drug-related effects on blood counts,
blood chemical values, or urinalysis results were
found (data not shown).
DISCUSSION
The results of these studies show that administra-
tion of the novel neuraminidase inhibitor zanamivir
directly to the respiratory tract is associated with sig-
nificant clinical and antiviral effects in adults with
naturally occurring influenzavirus infections. The
magnitude of the observed clinical benefit was a
one-day (approximately 20 percent) reduction in the
time to the alleviation of major influenza symptoms.
However, the degree of benefit was greater in those
with more pronounced illness, as indicated by the
presence of fever at enrollment, and in those treated
within 30 hours after the onset of symptoms. In
these groups the median times to the alleviation of
influenza symptoms were approximately 40 percent
less (shorter by three days) than that in the respec-
tive placebo group. These findings are consistent
with the relatively rapid resolution of uncomplicated
influenza in previously healthy adults and the need
for early antiviral drug administration. The magni-
tude of the clinical benefit observed in this study ap-
pears to be at least as great as that in earlier trials of
amantadine and rimantadine for acute febrile influ-
enza A illness in adults.17-20 In addition, as predicted
by the results of in vitro studies,8,9 tests in animal
models,8,10 and experimental studies in humans,21
the antiviral spectrum and clinical effectiveness of za-
namivir included influenza B virus infections.
As expected, zanamivir was of no benefit in per-
sons without laboratory-documented influenzavirus
infection. Although the clinical diagnosis of typical
influenza in adults is highly predictive of virological-
ly confirmed infection during brisk epidemics, in
our study a relatively high proportion of enrolled pa-
tients did not have confirmed influenza. This obser-
vation indicates the limitations of this approach and
the need for rapid viral diagnosis when the likeli-
hood of infection is not high.
Topical zanamivir was generally well tolerated, and
the frequency of local irritation was low. One source
of concern was that the inhalation of dry powder
would prove to be irritating in those with acute in-
fluenza, which can cause mucosal damage and air-
way hyperreactivity.12 Although we did not measure
pulmonary function, the more rapid resolution of
cough in recipients of zanamivir than in placebo re-
cipients is reassuring. Furthermore, previous studies
of uninfected patients with asthma found no evi-
dence of clinical intolerance or spirometric deterio-
ration after multiple-dose inhalations of zanamivir
for two weeks.22 Because of the severity of influenza
in patients with underlying disease of the airways
(such as asthma, chronic bronchitis, emphysema, or
cystic fibrosis) and the anticipated use of an anti-
influenza agent in these high-risk patients, it will be
important to collect further safety data in such pa-
tients. The administration of zanamivir did not im-
pair the humoral immune response to infection in
our patients.
Intranasal zanamivir did not significantly enhance
the clinical benefit observed with inhaled drug alone.
However, this study was not designed to detect dif-
ferences between the zanamivir groups, so it is pre-
mature to conclude that intranasal dosing was not
beneficial. For several outcome measures, the group
given both intranasal and inhaled zanamivir tended
to benefit more than the patients given placebo, even
though the former group had a higher proportion of
smokers and smoking is a risk factor for more severe
influenza.23 Intranasal zanamivir also reduced viral ti-
ters in the upper respiratory tract. Although this was
not tested directly in this study, such reductions
might reduce the risk of transmission of influenzavi-
rus. Sustained antiviral effects in the nasal passages
would probably be required to reduce the likelihood
of local complications such as otitis media and sinusi-
tis. In this regard, the number of complications lead-
ing to the use of antibiotics tended to be lower in the
zanamivir groups than in the placebo group, but our
samples were too small to detect significant differenc-
es in these relatively infrequent events.
The patterns of drug deposition are not well char-
acterized with the delivery devices used in these tri-
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als. Previous studies have shown broader distribution
within the nasal passages of materials administered by
intranasal drops than by coarse sprays.24,25 This dif-
ference in distribution is associated with less pro-
nounced antiviral effects of aerosolized agents than
of drops in experimental influenza11 and rhinovirus26
infections. Similarly, inhalations must be carefully
administered to reach the lower airways and avoid
being deposited on the oral mucosa or posterior
pharynx. Our patients gave themselves the study
drugs, which probably resulted in suboptimal deliv-
ery of zanamivir in some cases. Consequently, it re-
mains uncertain whether the effects observed in our
study represent the maximal benefits that might be
derived from antiviral treatment of acute influenza
with zanamivir. However, our findings indicate that
topically applied zanamivir is an effective therapy for
uncomplicated influenzavirus infections in adults,
especially when initiated early. Pharmacologic inhi-
bition of influenzavirus neuraminidase may prove to
be a useful therapeutic strategy.
Drs. Hayden, Treanor, Aoki, and Nicholson have served as ad hoc con-
sultants to Glaxo Wellcome.
APPENDIX
The following are members of the GG167 Influenza Study Group: Bel-
gium: G. Adam, Brussels; H. Van Pottelbergh, Buizingen; M. Godefroid,
Marche-on-Famenne; Finland: O. Ruuskanen and M. Makela, Turku;
France: A. Simmons, Linas; J. Luciani, Coligny; J. Richir, Lille; J.A. Cozic,
Nantes; M. Behar, Longpont sur Orge; Germany: R. Lehm, Stolpen; Italy:
F. Pregliasco, Milano; P. Crovari, Genova; the Netherlands: A. Osterhaus,
R. De Groot, A. Bohnen, P. Rothbarth, E. Claas, G. Rimmelzwaan, and
J.C. van der Woude, Rotterdam; Norway: H. Hauge, Eidsvaag; I. Hercz,
Hoevik; K. Innvik, Fyllingsdalen; M. Haegde Naess and O. Sand, Oslo;
T. Tomassen, Trondheim; Spain: C. Jane and J.M. Bordas, Barcelona;
M. Palomo, M. Alonso, and M.A. Villanueva, Madrid; Sweden: T. Sand-
berg, Goteberg; C. Ahlm, Umea; K. Pauksens, Uppsala; M. Glimaker, Dan-
deryd; United Kingdom: D.M. Fleming, Birmingham; M.F. Duffy, Liver-
pool; D.S.A. Khan, Coppull; K. Nicholson, Leicester; Canada: F. Aoki,
P. Orr, Winnipeg, Man.; B. Clecner, St. Jerome, Que.; J. Dylewski, Mon-
treal; K. Forward, Halifax, N.S.; L.J. Miedzinski, Edmonton, Alta.;
S. Walmsley, Toronto; K. Williams, Saskatoon, Sask.; D.E. Zoutman, King-
ston, Ont.; United States: J. Adelglass, R.C. Andruczk, Dallas; S. Becker,
Houston; S. Campbell, Tucson, Ariz.; V.A. Elinoff, Endwell, N.Y.; L.A.
Fischer, West Palm Beach, Fla.; L.I. Gilderman, Pembroke Pines, Fla.;
A. Graff, Fort Lauderdale, Fla.; F. Hayden and M. Lobo, Charlottesville,
Va.; D. Henry, Sandy, Utah; T.M. Howard, Fort Belvoir, Va.; B. Kerzner
and K.H. Williams, Baltimore; R. Kobayashi, Omaha, Nebr.; D.J. Mikolich,
Providence, R.I.; J. O’Rourke and J. Rubino, Raleigh, N.C.; S.A. Pace, Fort
Lewis, Wash.; L.E. Payne, Lakeland AFB, Tex.; G.L. Post, Englewood, Co-
lo.; A. Puopolo, Milford, Mass.; J. Rhudy, Salt Lake City; G.E. Ruoff,
Kalamazoo, Mich.; J. Ryder-Benz, Cedar Rapids, Iowa; J. Schoenberger,
Redwood City, Calif.; H.M. Serfer, Hollywood, Fla.; B.M. Sklar, Alameda,
Calif.; W. Sun, El Paso, Tex.; J. Treanor, Rochester, N.Y.; W. Whitlock, Fort
Gordon, Ga.
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